Atea Pharmaceuticals Inc. News, Atea Pharmaceuticals Inc. Quote, AVIR Quote

Atea Pharmaceuticals Inc. (NQ:AVIR) Delayed: 5.18 -0.09 (1.71%)

Prev. Close

$5.27

Today 6M 1Y 5Y

Open

$5.22

52 Wk High

$2.00

52 Wk Low

$1.15

Day High

$5.30

Day Low

$5.17

P/E

N/A

EPS

$0.00

Volume

251,134

Friends, Peers and Foes (?): COYA (more...)

ALERTS | RSS

Aug 13, 2026 08:08 AM Atea Pharmaceuticals (AVIR) PT Raised to $7 at Morgan Stanley
Aug 12, 2026 04:46 PM Form 10-Q Atea Pharmaceuticals, For: Jun 30
Aug 12, 2026 04:16 PM Form 8-K Atea Pharmaceuticals, For: Aug 12
Aug 12, 2026 04:14 PM Aviragen Therapeutics (AVIR) Tops Q2 EPS by 15c
Aug 12, 2026 04:05 PM Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 5, 2026 07:00 AM Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
Jul 28, 2026 07:00 AM Atea Pharmaceuticals HCV drug meets phase 3 trial endpoints
Jul 28, 2026 07:00 AM Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Jul 14, 2026 07:00 AM Atea Pharmaceuticals starts Phase 1 trial of AT-587 for hepatitis E
Jul 14, 2026 07:00 AM Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Entities mentioned with AVIR

View All Entities